共 43 条
- [1] Assessing myocardial perfusion in suspected coronary artery disease: rationale and design of the second phase 3, open-label multi-center study of flurpiridaz (F-18) injection for positron emission tomography (PET) imagingJOURNAL OF NUCLEAR CARDIOLOGY, 2021, 28 (03) : 1105 - 1116Bourque, Jamieson M.Hanson, Christopher A.Agostini, DenisBateman, Timothy M.Bax, Jeroen J.Beanlands, Rob S. B.Berman, Daniel S.Garcia, Ernest V.Heller, Gary V.Knuuti, JuhaniTamaki, NagaraUdelson, James E.Maddahi, Jamshid
- [2] Assessing myocardial perfusion in suspected coronary artery disease: rationale and design of the second phase 3, open-label multi-center study of flurpiridaz (F-18) injection for positron emission tomography (PET) imagingJournal of Nuclear Cardiology, 2021, 28 : 1105 - 1116Jamieson M. BourqueChristopher A. HansonDenis AgostiniTimothy M. BatemanJeroen J. BaxRob S. B. BeanlandsDaniel S. BermanErnest V. GarciaGary V. HellerJuhani KnuutiNagara TamakiJames E. UdelsonJamshid Maddahi
- [3] SITES OF PROSTATE CANCER RECURRENCE DELINEATED WITH 18F-FLUCICLOVINE POSITRON EMISSION TOMOGRAPHY IN PATIENTS WITH NEGATIVE OR EQUIVOCAL CONVENTIONAL IMAGINGJOURNAL OF UROLOGY, 2019, 201 (04): : E1100 - E1101Andriole, GeraldSiegel, Barry
- [4] A multi-center, open-label, non-randomized phase II study of elsamitrucin (SPI-28090) in patients with relapsed or refractory non-hodgkin's lymphoma (NHL).BLOOD, 2004, 104 (11) : 232B - 232BMohrbacher, ASanani, SIrwin, DEspina, BMMadrid, CLenaz, LRosales, R
- [5] Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 studyJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Wang, JiabeiPeng, TaoLiu, ChangZhang, LingZhu, GuangzhiZhang, XiaogangWang, XiaoqianLiu, Lianxin
- [6] A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy.JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS435 - TPS435Tran, BenCourtney, Kevin DaleSokolova, AlexandraHorvath, LisaDanila, Daniel CostinHawley, Jessica E.Pook, David WilliamBrown, Landon CarterWhang, Young E.Buetikofer, SimonWang, KejiaZorko, Nicholas
- [7] PROGRAMMED DEATH-LIGAND 1 POSITRON EMISSION TOMOGRAPHY IMAGING DURING NEOADJUVANT (CHEMO)RADIOTHERAPY IN ESOPHAGEAL AND RECTAL CANCER (PETNEC): A PROSPECTIVE NON-RANDOMIZED OPEN-LABEL SINGLE-CENTER PILOT STUDYJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A17 - A18Laengle, J.Tamandl, D.Schmid, R.Widder, J.Bergmann, M.Haug, A.
- [8] Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive careCYTOTHERAPY, 2014, 16 (02) : 234 - 244Bapsy, Poonamalle ParthasarathySharan, BandanaKumar, ChaitanyaDas, Rajeev PatrickRangarajan, BharathJain, MinishAttili, Venkata Sathya SureshSubramanian, SundaramAggarwal, ShyamSrivastava, MalaVaid, Ashok
- [9] An open-label, non-randomized, multi-center phase I study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Li, KaiwenShi, YehuiWu, JunyanZhou, LiyanYe, SuiwenLai, XiupingHuang, RobertTeng, YanYu, JiangangChai, XiaoyanHuang, Hai
- [10] Exploratory clinical trial of [18F]GP1 for imaging arterial or venous thromboembolism using positron emission tomography: interim analysis of an open-label, single center studyJOURNAL OF NUCLEAR MEDICINE, 2017, 58Jin, SoyoungLee, Jae SeungHan, YoungjinChae, Sun YoungOh, Seung JunLee, Sang JuChun, Sung JinNoh, MinsuCho, Yong PilKwon, Tae-WonKwon, Sun UckKoglin, NormanBerndt, MathiasStephens, AndrewMoon, Dae Hyuk